Patent application number | Description | Published |
20120064509 | Methods and compositions related thereto for detecting and identifying distinct species of nucleic acids from causative agents - Methods are described herein for detecting and identifying distinct species of nucleic acids, in a single container, for example, from a certain genus of infectious agents or otherwise causative agents comprising, for example, providing a forward PCR primer common to a homologous gene region between the distinct species, and providing a reverse PCR primer common to a homologous gene region between the distinct species, to thereby define a PCR target region amongst the species, and providing a first oligonucleotide probe specific to a nucleic acid sequence within the target region that is characteristic of a first species, providing a second oligonucleotide probe specific to a nucleic acid sequence within the target region that is characteristic of a second species, wherein the first and second oligonucleotide probes are each detectably labeled with distinctly different detectable labels, conducting a PCR reaction in the container by means of the primers to amplify the target region amongst the species, and detecting the distinct labels, thereby identifying distinct species of nucleic acids corresponding to distinct species of infectious agents. Methods are preferred, for example, wherein the infectious agent is a member of the Herpesviridae family. | 03-15-2012 |
20120070837 | CIP2A as a biomarker in detection of cervical cancer - The present invention provides methods and compositions for detecting cervical cancer in a human. The present invention provides CIP2A as a biomarker detectable in a biological sample from cervix of an individual, an increased expression of same is an indication of cervical cancer in the individual. CIP2A mRNA or protein can both serve as reliable biomarkers. In one embodiment, the present invention provides a combined use of CIP2A with at least one additional biomarker selected from the group consisting of Ki67, TOP2A, MCM2, MCM5, p14 | 03-22-2012 |
20120190046 | DEK as a urine based biomarker for bladder cancer - The present invention is directed to a method of detecting DEK protein in a urine sample. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by chemical-induced precipitation of urine proteins, followed by filtration-induced concentration and Western blot analysis to specifically detect DEK protein. The present method permits specific detection of DEK protein in urine as a biomarker for bladder cancer in humans. | 07-26-2012 |
20120196305 | Detection of a specific DEK isoform as a urine-based biomarker for bladder cancer - The present invention is directed to a method of detecting a DEK protein isoform 2 in a human urine sample using ELISA. Methods and compositions for detection of DEK isoform 2 in human urine are provided herein. The presence of DEK isoform 2 in urine is shown to correlate with bladder cancer in humans. | 08-02-2012 |
20130115599 | INCREASED CIP2A EXPRESSION AND BLADDER CANCER IN HUMANS - The present invention provides a method of detecting CIP2A protein in a bladder tissue. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by obtaining a bladder tissue from a human subject suspected of bladder cancer, followed by detecting CIP2A protein or mRNA levels in the bladder tissue using Western blot analysis or ELISA to specifically detect CIP2A protein or qRT-PCR to specifically detect CIP2A mRNA. The present method permits specific detection of CIP2A protein or mRNA in bladder tissue as a biomarker for bladder cancer in humans. | 05-09-2013 |
20130224738 | DETECTING DNA METHYLATION OF BCL2, CDKN2A AND NID2 GENES TO PREDICT BLADDER CANCER IN HUMANS - The present invention provides a method of detecting DNA methylation of a plurality of genes consisting of CDKN2A, BCL2 and NID2 in a urine sample from a human. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by obtaining a urine sample from a human subject suspected of bladder cancer, followed by detecting DNA methylation of CDKN2A, BCL2 AND NID2 in urine samples from the individual. The present method permits specific detection of DNA methylation of the selected gene promoters in urine as a biomarker for bladder cancer in humans. | 08-29-2013 |
20130230848 | Oligonucleotides Useful in Methods for Detecting and Characterizing Aspergillus fumigatus - Methods for using oligonucleotides in the detection of | 09-05-2013 |
20130288238 | Methods and Compositions for Detecting Serotypes of Chlamydia trachomatis Capable of Causing Lymphogranuloma Venereum - Disclosed are methods and compositions for conducting assays utilizing real-time polymerase chain reactions (“PCRs”) in detection of serotypes L I, L II, and L III, but not stereotype B, of | 10-31-2013 |
20130309683 | Methods and Compositions for Detecting and Identifying Species of Candida - Methods and compositions useful in the detection and identifcation of species of | 11-21-2013 |
20140295463 | ELISA Detection of Urine DEK to Predict and Diagnose Bladder Cancer in Humans - The present invention is directed to a method of detecting a DEK protein in a human urine sample using an ELISA assay. Methods and compositions for detection of DEK using mAb 260-6F9F6 (as detection antibody) and mAb 16-2C9C3 (as capture antibody) in human urine are provided herein. Specifically, the ELISA assay utilizes a capture mAb and a detection mAb to yield a high sensitivity of <50 ng/mL. The presence of DEK in urine is useful in predicting or diagnosing the occurrence of bladder cancer in humans. | 10-02-2014 |